HSC-4
HSC-4 is an orally active anti-inflammatory agent and a derivative of Hederacoside C (HY-N0253). HSC-4 inhibits the secretion of IL-6. HSC-4 exerts protective effects in mouse models of systemic sepsis and acute lung injury. HSC-4 can be used for the research of acute lung injury and systemic sepsis.
For research use only. We do not sell to patients.
- CAS No.: 3109806-14-3
- Formula: C45H73NO11
- Molecular Weight:804.06
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IL-6 |
In Vitro
HSC-4 (3.9-125 μM; 24 h) exhibits low cytotoxicity in RAW264.7 macrophages, with cell viability remaining above 83% even at concentrations up to 125 μM[1].
HSC-4 (2.3-60 μM; 2 h pre-incubation) potently inhibits LPS-induced IL-6 secretion in RAW264.7 macrophages, with extremely significant inhibitory effects observed at all tested concentrations ranging from 2.3 μM to 60 μM[1].
HSC-4 (2.3-60 μM; 2 h pre-incubation) inhibits LPS-induced TNF-α secretion in RAW264.7 macrophages, with significant inhibitory effects observed at concentrations of 2.3 μM, 20 μM and 60 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 macrophages
-
Concentration:3.9 μM, 7.8 μM, 15.6 μM, 31.3 μM, 62.5 μM, 125 μM
-
Incubation Time:24 h
-
Result:Showed negligible cytotoxicity across all tested concentrations, with cell viability values of 102.2% at 3.9 μM, 95.3% at 7.8 μM, 99.5% at 15.6 μM, 96.5% at 31.3 μM, 84.4% at 62.5 μM, and 83.2% at 125 μM.
-
Cell Line:LPS-stimulated RAW264.7 macrophages
-
Concentration:2.3 μM, 6.7 μM, 20 μM, 60 μM
-
Incubation Time:2 h pre-incubation
-
Result:Strongly inhibited LPS-induced IL-6 secretion in a concentration-dependent manner, with IL-6 levels of 28.7 pg/mL at 2.3 μM, 21.0 pg/mL at 6.7 μM, 11.5 pg/mL at 20 μM, and 5.6 pg/mL at 60 μM (model group IL-6 level: 58.1 pg/mL).
Exhibited highly significant inhibition at all tested concentrations (***P < 0.001 vs model group).\nInhibited LPS-induced TNF-α secretion, with TNF-α levels of 23.3 pg/mL at 2.3 μM, 35.0 pg/mL at 6.7 μM, 27.1 pg/mL at 20 μM, and 29.4 pg/mL at 60 μM (model group TNF-α level: 55.1 pg/mL).
Exhibited significant inhibition at 2.3 μM (***P < 0.001 vs model group), 20 μM (**P < 0.01 vs model group), and 60 μM (**P < 0.01 vs model group).
In Vivo
HSC-4 (50 mg/kg; p.o.; single treatment immediately after LPS challenge) exerts significant protective effects against LPS-induced acute lung injury[1].
HSC-4 (100-400 mg/kg; p.o.; daily; for 5 consecutive days) causes no significant hepatotoxicity or nephrotoxicity in KM mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, specific pathogen-free, systemic sepsis model via intraperitoneal LPS injection at 4 mg/kg)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; two doses (1 h pre-LPS and 1 h post-LPS)
-
Result:Significantly reduced IL-6 levels in the liver, heart, intestine, and lung compared to the model group, with efficacy comparable to or superior to dexamethasone and Hederacoside C.
Markedly alleviated LPS-induced tissue damage, including inflammatory cell infiltration and structural disruption, with comparable or superior protective effects in lung tissue relative to the positive control.
-
Animal Model:BALB/c (male, specific pathogen-free, acute lung injury model via intranasal LPS instillation at 2.9 mg/mL, 50 μL)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; single dose immediately post-LPS challenge
-
Result:Significantly reduced lung tissue levels of IL-1β, TNF-α, and IL-6 at 2 hours post-administration, with stronger inhibitory activity than dexamethasone at this time point.
Exerted maximal anti-inflammatory effect at 4 hours, with activity slightly weaker than dexamethasone.
Showed gradually declining inhibitory activity by 8 hours post-administration.
Chemical Information
-
CAS No. 3109806-14-3
-
Molecular Weight 804.06
-
Formula C45H73NO11
-
SMILES
O[C@H]1[C@]([H])(O[C@@H]2[C@@H](O)[C@@H](O)CO[C@]2(O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])CC=C6[C@@]4(C)CC[C@]7(C(NCC8CC8)=O)[C@@]6([H])CC(C)(C)CC7)([H])[C@]5(C)CC3)[H])O[C@@H](C)[C@H](O)[C@H]1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)